Pharmaceutical Drug Delivery Market by Route of Administration (Oral Drug Delivery, Pulmonary Drug Delivery, Injectable Drug Delivery, Nasal Drug Delivery, Ocular Drug Delivery, Topical Drug Delivery, and Others) and Application (Cancer, Diabetes, Respiratory Diseases, Cardiovascular Diseases, and Others): Global Opportunity Analysis and Industry Forecast, 2019–2026
The global pharmaceutical drug delivery market accounted for $1,200 million in 2018, and is expected to reach $1,733 million by 2026, registering a CAGR of 4.7% from 2019 to 2026.
Pharmaceutical drug delivery methods enable the introduction of therapeutic agents into the body. These drugs are administered through various routes, and selection of a suitable route of administration is crucial to achieve higher bioavailability at the site of action. Therefore, drug delivery systems are employed to achieve high drug targeting specificity, low systemic drug toxicity, and improved drug absorption rates. Nasal drug delivery system, ocular drug delivery, pulmonary drug delivery, and oral drug delivery system are some of the routes, which are used for drug administration. In addition, these systems are used in treatment of various chronic conditions such as cancer, cardiovascular diseases, and respiratory diseases.
The major factor that contributes to the growth of the global pharmaceutical drug delivery market include surge in awareness related to use of pharmaceutical drug delivery systems. Furthermore, the growth of the market is driven by other factors such as rise in healthcare expenditure and surge in governmental support for research in the field of drug delivery. In addition, surge in prevalence of various chronic diseases, which require the use of pharmaceutical drug delivery is another major factor that contributes toward the growth of the market. However, rise in number of drug recalls and drug failures restricts the growth of the global market. Conversely, high growth potential in developing economies is expected to offer lucrative opportunities during the forecast period.
The global pharmaceutical drug delivery market is segmented into route of administration, application, and region. On the basis of route of administration, it is categorized into oral drug delivery system, pulmonary drug delivery, ocular drug delivery systems, nasal drug delivery system, ocular drug delivery, topical drug delivery, and others. By application, it is segregated into cancer, diabetes, respiratory diseases, cardiovascular diseases, and others. Region wise, it is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, and rest of LAMEA). .
KEY BENEFITS FOR STAKEHOLDERS
Pharmaceutical drug delivery methods enable the introduction of therapeutic agents into the body. These drugs are administered through various routes, and selection of a suitable route of administration is crucial to achieve higher bioavailability at the site of action. Therefore, drug delivery systems are employed to achieve high drug targeting specificity, low systemic drug toxicity, and improved drug absorption rates. Nasal drug delivery system, ocular drug delivery, pulmonary drug delivery, and oral drug delivery system are some of the routes, which are used for drug administration. In addition, these systems are used in treatment of various chronic conditions such as cancer, cardiovascular diseases, and respiratory diseases.
The major factor that contributes to the growth of the global pharmaceutical drug delivery market include surge in awareness related to use of pharmaceutical drug delivery systems. Furthermore, the growth of the market is driven by other factors such as rise in healthcare expenditure and surge in governmental support for research in the field of drug delivery. In addition, surge in prevalence of various chronic diseases, which require the use of pharmaceutical drug delivery is another major factor that contributes toward the growth of the market. However, rise in number of drug recalls and drug failures restricts the growth of the global market. Conversely, high growth potential in developing economies is expected to offer lucrative opportunities during the forecast period.
The global pharmaceutical drug delivery market is segmented into route of administration, application, and region. On the basis of route of administration, it is categorized into oral drug delivery system, pulmonary drug delivery, ocular drug delivery systems, nasal drug delivery system, ocular drug delivery, topical drug delivery, and others. By application, it is segregated into cancer, diabetes, respiratory diseases, cardiovascular diseases, and others. Region wise, it is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, and rest of LAMEA). .
KEY BENEFITS FOR STAKEHOLDERS
- This report entails a detailed quantitative analysis along with the current global pharmaceutical drug delivery systemmarket trends from 2019 to 2026 to identify the prevailing opportunities along with the strategic assessments.
- The market size and estimations are based on a comprehensive analysis of key developments in the industry.
- A qualitative analysis based on innovative products facilitates strategic business planning.
- The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market
- By Route of administration
- Oral drug delivery
- Pulmonary drug delivery
- Injectable drug delivery
- Nasal drug delivery
- Ocular drug delivery
- Topical Drug Delivery
- Others
- By Application
- Cancer
- Diabetes
- Respiratory Diseases
- Cardiovascular Diseases
- Others
- By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
- List of key players profiled in the report:
- Bayer AG
- Becton, Dickinson And Company
- F. Hoffmann-La Roche AG
- GlaxoSmithKline Plc
- Johnson & Johnson
- Merck & Co., Inc.
- Novartis AG
- 3M Company
- Pfizer Inc.
- Sanofi
- Novartis AG
- Antares Pharma, Inc.
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.2.1. List of key players profiled in the report
1.3. Research methodology
1.3.1. Primary research
1.3.2. Secondary research
1.3.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Top player positioning
3.2.1. Top investment pockets
3.3. Key forces shaping Pharmaceutical drug delivery industry/market
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Rise in prevalence of chronic disorders which require the use of drug delivery systems
3.4.1.2. Surge in healthcare expenditure worldwide
3.4.1.3. Rise in number of developments made by key players in drug delivery system market
3.4.2. Restraint
3.4.2.1. Rise in number of drug recalls and drug failures
3.4.3. Opportunity
3.4.3.1. High growth potential in developing economies
3.4.4. Impact Analyses
CHAPTER 4: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION
4.1. Overview
4.1.1. Market size and forecast
4.2. Oral drug delivery system
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis by country
4.3. Nasal drug delivery system
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis by country
4.4. Ocular drug delivery systems
4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis by country
4.5. Topical drug delivery system
4.5.1. Key market trends, growth factors, and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market analysis by country
4.6. Other drug delivery system
4.6.1. Key market trends, growth factors, and opportunities
4.6.2. Market size and forecast, by region
4.6.3. Market analysis by country
CHAPTER 5: PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Cancer
5.2.1. Market size and forecast, by region
5.2.2. Market analysis by country
5.3. Diabetes
5.3.1. Market size and forecast, by region
5.3.2. Market analysis by country
5.4. Cardiovascular diseases
5.4.1. Market size and forecast, by region
5.4.2. Market analysis by country
5.5. Others
5.5.1. Market size and forecast, by region
5.5.2. Market analysis by country
CHAPTER 6: PHARMACEUTICAL DRUG DELIVERY MARKET, BY REGION
6.1. Overview
6.1.1. Market size and forecast
6.2. North America
6.2.1. Key market trends and opportunities
6.2.2. Market analysis, by country
6.2.2.1. U.S.
6.2.2.1.1. U.S. market size and forecast, by route of administration
6.2.2.1.2. U.S. market size and forecast, by application
6.2.2.2. Canada
6.2.2.2.1. Canada market size and forecast, by route of administration
6.2.2.2.2. Canada market size and forecast, by application
6.2.2.3. Mexico
6.2.2.3.1. Mexico market size and forecast, by route of administration
6.2.2.3.2. Mexico market size and forecast, by application
6.2.3. North America market size and forecast, by route of administration
6.2.4. North America market size and forecast, by application
6.3. Europe
6.3.1. Key market trends and opportunities
6.3.2. Market analysis, by country
6.3.2.1. Germany
6.3.2.1.1. Germany market size and forecast, by route of administration
6.3.2.1.2. Germany market size and forecast, by application
6.3.2.2. France
6.3.2.2.1. France market size and forecast, by route of administration
6.3.2.2.2. France market size and forecast, by application
6.3.2.3. UK
6.3.2.3.1. UK market size and forecast, by route of administration
6.3.2.3.2. UK market size and forecast, by application
6.3.2.4. Italy
6.3.2.4.1. Italy market size and forecast, by route of administration
6.3.2.4.2. Italy market size and forecast, by application
6.3.2.5. Rest of Europe
6.3.2.5.1. Rest of Europe market size and forecast, by route of administration
6.3.2.5.2. Rest of Europe market size and forecast, by application
6.3.3. Europe market size and forecast, by route of administration
6.3.4. Europe market size and forecast, by application
6.4. Asia-Pacific
6.4.1. Key market trends and opportunities
6.4.2. Market analysis, by country
6.4.2.1. Japan
6.4.2.1.1. Japan market size and forecast, by route of administration
6.4.2.1.2. Japan market size and forecast, by application
6.4.2.2. China
6.4.2.2.1. China market size and forecast, by route of administration
6.4.2.2.2. China market size and forecast, by application
6.4.2.3. India
6.4.2.3.1. India market size and forecast, by route of administration
6.4.2.3.2. India market size and forecast, by application
6.4.2.4. Rest of Asia-Pacific
6.4.2.4.1. Rest of Asia-Pacific market size and forecast, by route of administration
6.4.2.4.2. Rest of Asia-Pacific market size and forecast, by application
6.4.3. Asia-Pacific market size and forecast, by route of administration
6.4.4. Asia-Pacific market size and forecast, by application
6.5. LAMEA
6.5.1. Key market trends and opportunities
6.5.2. Market analysis, by country
6.5.2.1. Brazil
6.5.2.1.1. Brazil market size and forecast, by route of administration
6.5.2.1.2. Brazil market size and forecast, by application
6.5.2.2. South Africa
6.5.2.2.1. South Africa market size and forecast, by route of administration
6.5.2.2.2. South Africa market size and forecast, by application
6.5.2.3. Saudi Arabia
6.5.2.3.1. Saudi Arabia market size and forecast, by route of administration
6.5.2.3.2. Saudi Arabia market size and forecast, by application
6.5.2.4. Rest of LAMEA
6.5.2.4.1. Rest of LAMEA market size and forecast, by route of administration
6.5.2.4.2. Rest of LAMEA market size and forecast, by application
6.5.3. LAMEA market size and forecast, by route of administration
6.5.4. LAMEA market size and forecast, by application
CHAPTER 7: COMPANY PROFILES
7.1. Bayer AG.
7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product portfolio
7.1.5. Business performance
7.2. BECTON, DICKINSON AND COMPANY
7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product portfolio
7.2.5. Business performance
7.2.6. Key strategic moves and developments
7.3. F. Hoffmann-La Roche AG
7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Product portfolio
7.3.5. Business performance
7.3.6. Key strategic moves and developments
7.4. GlaxoSmithKline Plc
7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product portfolio
7.4.5. Business performance
7.4.6. Key strategic moves and developments
7.5. JOHNSON & JOHNSON
7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product portfolio
7.5.5. Business performance
7.6. Merck & Co., Inc.
7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product portfolio
7.6.5. Business performance
7.7. Novartis AG
7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product portfolio
7.7.5. Business performance
7.8. 3M Company
7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product portfolio
7.8.5. Business performance
7.8.6. Key strategic moves and developments
7.9. Pfizer Inc.
7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product portfolio
7.9.5. Business performance
7.10. SANOFI
7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Product portfolio
7.10.5. Business performance
7.10.1. Key strategic moves and developments
1.1. Report description
1.2. Key market segments
1.2.1. List of key players profiled in the report
1.3. Research methodology
1.3.1. Primary research
1.3.2. Secondary research
1.3.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Top player positioning
3.2.1. Top investment pockets
3.3. Key forces shaping Pharmaceutical drug delivery industry/market
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Rise in prevalence of chronic disorders which require the use of drug delivery systems
3.4.1.2. Surge in healthcare expenditure worldwide
3.4.1.3. Rise in number of developments made by key players in drug delivery system market
3.4.2. Restraint
3.4.2.1. Rise in number of drug recalls and drug failures
3.4.3. Opportunity
3.4.3.1. High growth potential in developing economies
3.4.4. Impact Analyses
CHAPTER 4: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION
4.1. Overview
4.1.1. Market size and forecast
4.2. Oral drug delivery system
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis by country
4.3. Nasal drug delivery system
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis by country
4.4. Ocular drug delivery systems
4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis by country
4.5. Topical drug delivery system
4.5.1. Key market trends, growth factors, and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market analysis by country
4.6. Other drug delivery system
4.6.1. Key market trends, growth factors, and opportunities
4.6.2. Market size and forecast, by region
4.6.3. Market analysis by country
CHAPTER 5: PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Cancer
5.2.1. Market size and forecast, by region
5.2.2. Market analysis by country
5.3. Diabetes
5.3.1. Market size and forecast, by region
5.3.2. Market analysis by country
5.4. Cardiovascular diseases
5.4.1. Market size and forecast, by region
5.4.2. Market analysis by country
5.5. Others
5.5.1. Market size and forecast, by region
5.5.2. Market analysis by country
CHAPTER 6: PHARMACEUTICAL DRUG DELIVERY MARKET, BY REGION
6.1. Overview
6.1.1. Market size and forecast
6.2. North America
6.2.1. Key market trends and opportunities
6.2.2. Market analysis, by country
6.2.2.1. U.S.
6.2.2.1.1. U.S. market size and forecast, by route of administration
6.2.2.1.2. U.S. market size and forecast, by application
6.2.2.2. Canada
6.2.2.2.1. Canada market size and forecast, by route of administration
6.2.2.2.2. Canada market size and forecast, by application
6.2.2.3. Mexico
6.2.2.3.1. Mexico market size and forecast, by route of administration
6.2.2.3.2. Mexico market size and forecast, by application
6.2.3. North America market size and forecast, by route of administration
6.2.4. North America market size and forecast, by application
6.3. Europe
6.3.1. Key market trends and opportunities
6.3.2. Market analysis, by country
6.3.2.1. Germany
6.3.2.1.1. Germany market size and forecast, by route of administration
6.3.2.1.2. Germany market size and forecast, by application
6.3.2.2. France
6.3.2.2.1. France market size and forecast, by route of administration
6.3.2.2.2. France market size and forecast, by application
6.3.2.3. UK
6.3.2.3.1. UK market size and forecast, by route of administration
6.3.2.3.2. UK market size and forecast, by application
6.3.2.4. Italy
6.3.2.4.1. Italy market size and forecast, by route of administration
6.3.2.4.2. Italy market size and forecast, by application
6.3.2.5. Rest of Europe
6.3.2.5.1. Rest of Europe market size and forecast, by route of administration
6.3.2.5.2. Rest of Europe market size and forecast, by application
6.3.3. Europe market size and forecast, by route of administration
6.3.4. Europe market size and forecast, by application
6.4. Asia-Pacific
6.4.1. Key market trends and opportunities
6.4.2. Market analysis, by country
6.4.2.1. Japan
6.4.2.1.1. Japan market size and forecast, by route of administration
6.4.2.1.2. Japan market size and forecast, by application
6.4.2.2. China
6.4.2.2.1. China market size and forecast, by route of administration
6.4.2.2.2. China market size and forecast, by application
6.4.2.3. India
6.4.2.3.1. India market size and forecast, by route of administration
6.4.2.3.2. India market size and forecast, by application
6.4.2.4. Rest of Asia-Pacific
6.4.2.4.1. Rest of Asia-Pacific market size and forecast, by route of administration
6.4.2.4.2. Rest of Asia-Pacific market size and forecast, by application
6.4.3. Asia-Pacific market size and forecast, by route of administration
6.4.4. Asia-Pacific market size and forecast, by application
6.5. LAMEA
6.5.1. Key market trends and opportunities
6.5.2. Market analysis, by country
6.5.2.1. Brazil
6.5.2.1.1. Brazil market size and forecast, by route of administration
6.5.2.1.2. Brazil market size and forecast, by application
6.5.2.2. South Africa
6.5.2.2.1. South Africa market size and forecast, by route of administration
6.5.2.2.2. South Africa market size and forecast, by application
6.5.2.3. Saudi Arabia
6.5.2.3.1. Saudi Arabia market size and forecast, by route of administration
6.5.2.3.2. Saudi Arabia market size and forecast, by application
6.5.2.4. Rest of LAMEA
6.5.2.4.1. Rest of LAMEA market size and forecast, by route of administration
6.5.2.4.2. Rest of LAMEA market size and forecast, by application
6.5.3. LAMEA market size and forecast, by route of administration
6.5.4. LAMEA market size and forecast, by application
CHAPTER 7: COMPANY PROFILES
7.1. Bayer AG.
7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product portfolio
7.1.5. Business performance
7.2. BECTON, DICKINSON AND COMPANY
7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product portfolio
7.2.5. Business performance
7.2.6. Key strategic moves and developments
7.3. F. Hoffmann-La Roche AG
7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Product portfolio
7.3.5. Business performance
7.3.6. Key strategic moves and developments
7.4. GlaxoSmithKline Plc
7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product portfolio
7.4.5. Business performance
7.4.6. Key strategic moves and developments
7.5. JOHNSON & JOHNSON
7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product portfolio
7.5.5. Business performance
7.6. Merck & Co., Inc.
7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product portfolio
7.6.5. Business performance
7.7. Novartis AG
7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product portfolio
7.7.5. Business performance
7.8. 3M Company
7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product portfolio
7.8.5. Business performance
7.8.6. Key strategic moves and developments
7.9. Pfizer Inc.
7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product portfolio
7.9.5. Business performance
7.10. SANOFI
7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Product portfolio
7.10.5. Business performance
7.10.1. Key strategic moves and developments
LIST OF TABLES
TABLE 01. GLOBAL PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2018-2026 ($MILLION )
TABLE 02. ORAL PHARMACEUTICAL DRUG DELIVERY MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 03. NASAL PHARMACEUTICAL DRUG DELIVERY MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 04. OCULAR PHARMACEUTICAL DRUG DELIVERY MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 05. TOPICAL PHARMACEUTICAL DRUG DELIVERY MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 06. OTHERS PHARMACEUTICAL DRUG DELIVERY MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 07. GLOBAL PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2018-2026 ($MILLION )
TABLE 08. PHARMACEUTICAL DRUG DELIVERY MARKET FOR CANCER, BY REGION, 2018–2026 ($MILLION)
TABLE 09. PHARMACEUTICAL DRUG DELIVERY MARKET FOR DIABETES, BY REGION, 2018–2026 ($MILLION)
TABLE 10. PHARMACEUTICAL DRUG DELIVERY MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2018–2026 ($MILLION)
TABLE 11. PHARMACEUTICAL DRUG DELIVERY MARKET FOR OTHERS, BY REGION, 2018–2026 ($MILLION)
TABLE 12. PHARMACEUTICAL DRUG DELIVERY MARKET, BY REGION, 2018-2026 ($MILLION )
TABLE 13. NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET REVENUE, BY COUNTRY, 2019–2026 ($MILLION)
TABLE 14. U.S. PHARMACEUTICAL DRUG DELIVERY MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2019–2026 ($MILLION)
TABLE 15. U.S. PHARMACEUTICAL DRUG DELIVERY MARKET REVENUE, BY APPLICATION, 2019–2026 ($MILLION)
TABLE 16. CANADA PHARMACEUTICAL DRUG DELIVERY MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2019–2026 ($MILLION)
TABLE 17. CANADA PHARMACEUTICAL DRUG DELIVERY MARKET REVENUE, BY APPLICATION, 2019–2026 ($MILLION)
TABLE 18. MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2019–2026 ($MILLION)
TABLE 19. MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET REVENUE, BY APPLICATION, 2019–2026 ($MILLION)
TABLE 20. NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2019–2026($MILLION)
TABLE 21. NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET REVENUE, BY APPLICATION, 2019–2026($MILLION)
TABLE 22. EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET REVENUE, BY COUNTRY, 2019–2026 ($MILLION)
TABLE 23. GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2019–2026 ($MILLION)
TABLE 24. GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET REVENUE, BY APPLICATION, 2019–2026 ($MILLION)
TABLE 25. FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2019–2026 ($MILLION)
TABLE 26. FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET REVENUE, BY APPLICATION, 2019–2026 ($MILLION)
TABLE 27. UK PHARMACEUTICAL DRUG DELIVERY MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2019–2026 ($MILLION)
TABLE 28. UK PHARMACEUTICAL DRUG DELIVERY MARKET REVENUE, BY APPLICATION, 2019–2026 ($MILLION)
TABLE 29. ITALY PHARMACEUTICAL DRUG DELIVERY MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2019–2026 ($MILLION)
TABLE 30. ITALY PHARMACEUTICAL DRUG DELIVERY MARKET REVENUE, BY APPLICATION, 2019–2026 ($MILLION)
TABLE 31. REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2019–2026 ($MILLION)
TABLE 32. REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET REVENUE, BY APPLICATION, 2019–2026 ($MILLION)
TABLE 33. EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2019–2026($MILLION)
TABLE 34. EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET REVENUE, BY APPLICATION, 2019–2026($MILLION)
TABLE 35. ASIA-PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET REVENUE, BY COUNTRY, 2019–2026 ($MILLION)
TABLE 36. JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2019–2026 ($MILLION)
TABLE 37. JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET REVENUE, BY APPLICATION, 2019–2026 ($MILLION)
TABLE 38. CHINA PHARMACEUTICAL DRUG DELIVERY MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2019–2026 ($MILLION)
TABLE 39. CHINA PHARMACEUTICAL DRUG DELIVERY MARKET REVENUE, BY APPLICATION, 2019–2026 ($MILLION)
TABLE 40. INDIA PHARMACEUTICAL DRUG DELIVERY MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2019–2026 ($MILLION)
TABLE 41. INDIA PHARMACEUTICAL DRUG DELIVERY MARKET REVENUE, BY APPLICATION, 2019–2026 ($MILLION)
TABLE 42. REST OF ASIA-PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2019–2026 ($MILLION)
TABLE 43. REST OF ASIA-PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET REVENUE, BY APPLICATION, 2019–2026 ($MILLION)
TABLE 44. ASIA-PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2019–2026($MILLION)
TABLE 45. ASIA-PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET REVENUE, BY APPLICATION, 2019–2026($MILLION)
TABLE 46. LAMEA PHARMACEUTICAL DRUG DELIVERY MARKET REVENUE, BY COUNTRY, 2019–2026 ($MILLION)
TABLE 47. BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2019–2026 ($MILLION)
TABLE 48. BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET REVENUE, BY APPLICATION, 2019–2026 ($MILLION)
TABLE 49. SOUTH AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2019–2026 ($MILLION)
TABLE 50. SOUTH AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET REVENUE, BY APPLICATION, 2019–2026 ($MILLION)
TABLE 51. SAUDI ARABIA PHARMACEUTICAL DRUG DELIVERY MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2019–2026 ($MILLION)
TABLE 52. SAUDI ARABIA PHARMACEUTICAL DRUG DELIVERY MARKET REVENUE, BY APPLICATION, 2019–2026 ($MILLION)
TABLE 53. REST OF LAMEA PHARMACEUTICAL DRUG DELIVERY MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2019–2026 ($MILLION)
TABLE 54. REST OF LAMEA PHARMACEUTICAL DRUG DELIVERY MARKET REVENUE, BY APPLICATION, 2019–2026 ($MILLION)
TABLE 55. LAMEA PHARMACEUTICAL DRUG DELIVERY MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2019–2026($MILLION)
TABLE 56. LAMEA PHARMACEUTICAL DRUG DELIVERY MARKET REVENUE, BY APPLICATION, 2019–2026($MILLION)
TABLE 57. BAYER: COMPANY SNAPSHOT
TABLE 58. BAYER: OPERATING SEGMENTS
TABLE 59. BAYER AG.: PRODUCT PORTFOLIO:
TABLE 60. BD: COMPANY SNAPSHOT
TABLE 61. BECTON, DICKINSON AND COMPANY.: OPERATING SEGMENTS
TABLE 62. BECTON, DICKINSON AND COMPANY: PRODUCT PORTFOLIO
TABLE 63. ROCHE: COMPANY SNAPSHOT
TABLE 64. ROCHE: OPERATING SEGMENTS
TABLE 65. ROCHE: PRODUCT PORTFOLIO
TABLE 66. GSK: COMPANY SNAPSHOT
TABLE 67. GSK: OPERATING SEGMENTS
TABLE 68. GSK: PRODUCT PORTFOLIO
TABLE 69. J&J: COMPANY SNAPSHOT
TABLE 70. J&J: OPERATING SEGMENTS
TABLE 71. J&J: PRODUCT PORTFOLIO
TABLE 72. MERCK: COMPANY SNAPSHOT
TABLE 73. 3M: OPERATING SEGMENTS
TABLE 74. MERCK: PRODUCT PORTFOLIO
TABLE 75. NOVARTIS: COMPANY SNAPSHOT
TABLE 76. NOVARTIS: OPERATING SEGMENTS
TABLE 77. NOVARTIS: PRODUCT PORTFOLIO
TABLE 78. 3M: SNAPSHOT
TABLE 79. 3M COMPANY: OPERATING SEGMENTS
TABLE 80. 3M COMPANY: PRODUCT PORTFOLIO
TABLE 81. PFIZER: COMPANY SNAPSHOT
TABLE 82. PFIZER: OPERATING SEGMENTS
TABLE 83. PFIZER: PRODUCT PORTFOLIO
TABLE 84. SANOFI: COMPANY SNAPSHOT
TABLE 85. SANOFI: PRODUCT SEGMENTS
TABLE 86. SANOFI: PRODUCT PORTFOLIO
TABLE 01. GLOBAL PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2018-2026 ($MILLION )
TABLE 02. ORAL PHARMACEUTICAL DRUG DELIVERY MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 03. NASAL PHARMACEUTICAL DRUG DELIVERY MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 04. OCULAR PHARMACEUTICAL DRUG DELIVERY MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 05. TOPICAL PHARMACEUTICAL DRUG DELIVERY MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 06. OTHERS PHARMACEUTICAL DRUG DELIVERY MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 07. GLOBAL PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2018-2026 ($MILLION )
TABLE 08. PHARMACEUTICAL DRUG DELIVERY MARKET FOR CANCER, BY REGION, 2018–2026 ($MILLION)
TABLE 09. PHARMACEUTICAL DRUG DELIVERY MARKET FOR DIABETES, BY REGION, 2018–2026 ($MILLION)
TABLE 10. PHARMACEUTICAL DRUG DELIVERY MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2018–2026 ($MILLION)
TABLE 11. PHARMACEUTICAL DRUG DELIVERY MARKET FOR OTHERS, BY REGION, 2018–2026 ($MILLION)
TABLE 12. PHARMACEUTICAL DRUG DELIVERY MARKET, BY REGION, 2018-2026 ($MILLION )
TABLE 13. NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET REVENUE, BY COUNTRY, 2019–2026 ($MILLION)
TABLE 14. U.S. PHARMACEUTICAL DRUG DELIVERY MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2019–2026 ($MILLION)
TABLE 15. U.S. PHARMACEUTICAL DRUG DELIVERY MARKET REVENUE, BY APPLICATION, 2019–2026 ($MILLION)
TABLE 16. CANADA PHARMACEUTICAL DRUG DELIVERY MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2019–2026 ($MILLION)
TABLE 17. CANADA PHARMACEUTICAL DRUG DELIVERY MARKET REVENUE, BY APPLICATION, 2019–2026 ($MILLION)
TABLE 18. MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2019–2026 ($MILLION)
TABLE 19. MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET REVENUE, BY APPLICATION, 2019–2026 ($MILLION)
TABLE 20. NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2019–2026($MILLION)
TABLE 21. NORTH AMERICA PHARMACEUTICAL DRUG DELIVERY MARKET REVENUE, BY APPLICATION, 2019–2026($MILLION)
TABLE 22. EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET REVENUE, BY COUNTRY, 2019–2026 ($MILLION)
TABLE 23. GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2019–2026 ($MILLION)
TABLE 24. GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET REVENUE, BY APPLICATION, 2019–2026 ($MILLION)
TABLE 25. FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2019–2026 ($MILLION)
TABLE 26. FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET REVENUE, BY APPLICATION, 2019–2026 ($MILLION)
TABLE 27. UK PHARMACEUTICAL DRUG DELIVERY MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2019–2026 ($MILLION)
TABLE 28. UK PHARMACEUTICAL DRUG DELIVERY MARKET REVENUE, BY APPLICATION, 2019–2026 ($MILLION)
TABLE 29. ITALY PHARMACEUTICAL DRUG DELIVERY MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2019–2026 ($MILLION)
TABLE 30. ITALY PHARMACEUTICAL DRUG DELIVERY MARKET REVENUE, BY APPLICATION, 2019–2026 ($MILLION)
TABLE 31. REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2019–2026 ($MILLION)
TABLE 32. REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET REVENUE, BY APPLICATION, 2019–2026 ($MILLION)
TABLE 33. EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2019–2026($MILLION)
TABLE 34. EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET REVENUE, BY APPLICATION, 2019–2026($MILLION)
TABLE 35. ASIA-PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET REVENUE, BY COUNTRY, 2019–2026 ($MILLION)
TABLE 36. JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2019–2026 ($MILLION)
TABLE 37. JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET REVENUE, BY APPLICATION, 2019–2026 ($MILLION)
TABLE 38. CHINA PHARMACEUTICAL DRUG DELIVERY MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2019–2026 ($MILLION)
TABLE 39. CHINA PHARMACEUTICAL DRUG DELIVERY MARKET REVENUE, BY APPLICATION, 2019–2026 ($MILLION)
TABLE 40. INDIA PHARMACEUTICAL DRUG DELIVERY MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2019–2026 ($MILLION)
TABLE 41. INDIA PHARMACEUTICAL DRUG DELIVERY MARKET REVENUE, BY APPLICATION, 2019–2026 ($MILLION)
TABLE 42. REST OF ASIA-PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2019–2026 ($MILLION)
TABLE 43. REST OF ASIA-PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET REVENUE, BY APPLICATION, 2019–2026 ($MILLION)
TABLE 44. ASIA-PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2019–2026($MILLION)
TABLE 45. ASIA-PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET REVENUE, BY APPLICATION, 2019–2026($MILLION)
TABLE 46. LAMEA PHARMACEUTICAL DRUG DELIVERY MARKET REVENUE, BY COUNTRY, 2019–2026 ($MILLION)
TABLE 47. BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2019–2026 ($MILLION)
TABLE 48. BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET REVENUE, BY APPLICATION, 2019–2026 ($MILLION)
TABLE 49. SOUTH AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2019–2026 ($MILLION)
TABLE 50. SOUTH AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET REVENUE, BY APPLICATION, 2019–2026 ($MILLION)
TABLE 51. SAUDI ARABIA PHARMACEUTICAL DRUG DELIVERY MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2019–2026 ($MILLION)
TABLE 52. SAUDI ARABIA PHARMACEUTICAL DRUG DELIVERY MARKET REVENUE, BY APPLICATION, 2019–2026 ($MILLION)
TABLE 53. REST OF LAMEA PHARMACEUTICAL DRUG DELIVERY MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2019–2026 ($MILLION)
TABLE 54. REST OF LAMEA PHARMACEUTICAL DRUG DELIVERY MARKET REVENUE, BY APPLICATION, 2019–2026 ($MILLION)
TABLE 55. LAMEA PHARMACEUTICAL DRUG DELIVERY MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2019–2026($MILLION)
TABLE 56. LAMEA PHARMACEUTICAL DRUG DELIVERY MARKET REVENUE, BY APPLICATION, 2019–2026($MILLION)
TABLE 57. BAYER: COMPANY SNAPSHOT
TABLE 58. BAYER: OPERATING SEGMENTS
TABLE 59. BAYER AG.: PRODUCT PORTFOLIO:
TABLE 60. BD: COMPANY SNAPSHOT
TABLE 61. BECTON, DICKINSON AND COMPANY.: OPERATING SEGMENTS
TABLE 62. BECTON, DICKINSON AND COMPANY: PRODUCT PORTFOLIO
TABLE 63. ROCHE: COMPANY SNAPSHOT
TABLE 64. ROCHE: OPERATING SEGMENTS
TABLE 65. ROCHE: PRODUCT PORTFOLIO
TABLE 66. GSK: COMPANY SNAPSHOT
TABLE 67. GSK: OPERATING SEGMENTS
TABLE 68. GSK: PRODUCT PORTFOLIO
TABLE 69. J&J: COMPANY SNAPSHOT
TABLE 70. J&J: OPERATING SEGMENTS
TABLE 71. J&J: PRODUCT PORTFOLIO
TABLE 72. MERCK: COMPANY SNAPSHOT
TABLE 73. 3M: OPERATING SEGMENTS
TABLE 74. MERCK: PRODUCT PORTFOLIO
TABLE 75. NOVARTIS: COMPANY SNAPSHOT
TABLE 76. NOVARTIS: OPERATING SEGMENTS
TABLE 77. NOVARTIS: PRODUCT PORTFOLIO
TABLE 78. 3M: SNAPSHOT
TABLE 79. 3M COMPANY: OPERATING SEGMENTS
TABLE 80. 3M COMPANY: PRODUCT PORTFOLIO
TABLE 81. PFIZER: COMPANY SNAPSHOT
TABLE 82. PFIZER: OPERATING SEGMENTS
TABLE 83. PFIZER: PRODUCT PORTFOLIO
TABLE 84. SANOFI: COMPANY SNAPSHOT
TABLE 85. SANOFI: PRODUCT SEGMENTS
TABLE 86. SANOFI: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 01. GLOBAL PHARMACEUTICAL DRUG DELIVERY MARKET SEGMENTATION
FIGURE 02. TOP PLAYER POSITIONING, 2018
FIGURE 03. TOP INVESTMENT POCKETS
FIGURE 04. MODERATE BARGAINING POWER OF SUPPLIER
FIGURE 05. LOW BARGAINING POWER OF BUYERS
FIGURE 06. LOW THREAT OF SUBSTITUTES
FIGURE 07. HIGH INTENSITY OF RIVALRY
FIGURE 08. LOW THREAT OF NEW ENTRANT
FIGURE 09. IMPACT ANALYSES, PHARMACEUTICAL DRUG DELIVERY MARKET
FIGURE 10. COMPARATIVE SHARE ANALYSIS OF ORAL PHARMACEUTICAL DRUG DELIVERY MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 11. COMPARATIVE SHARE ANALYSIS OF NASAL PHARMACEUTICAL DRUG DELIVERY MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF OCULAR PHARMACEUTICAL DRUG DELIVERY MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF TOPICAL PHARMACEUTICAL DRUG DELIVERY MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF OTHERS PHARMACEUTICAL DRUG DELIVERY MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 15. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL DRUG DELIVERY MARKET FOR CANCER, BY COUNTRY, 2018 & 2026 (%)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL DRUG DELIVERY MARKET FOR DIABETES, BY COUNTRY, 2018 & 2026 (%)
FIGURE 17. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL DRUG DELIVERY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2018 & 2026 (%)
FIGURE 18. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL DRUG DELIVERY MARKET FOR OTHERS, BY COUNTRY, 2018 & 2026 (%)
FIGURE 19. U.S. PHARMACEUTICAL DRUG DELIVERY MARKET, 2018-2026 ($MILLION)
FIGURE 20. CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, 2018-2026 ($MILLION)
FIGURE 21. MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, 2018-2026 ($MILLION)
FIGURE 22. GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, 2018-2026 ($MILLION)
FIGURE 23. FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, 2018-2026 ($MILLION)
FIGURE 24. UK PHARMACEUTICAL DRUG DELIVERY MARKET, 2018-2026 ($MILLION)
FIGURE 25. ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, 2018-2026 ($MILLION)
FIGURE 26. REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, 2018-2026 ($MILLION)
FIGURE 27. JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, 2018-2026 ($MILLION)
FIGURE 28. CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, 2018-2026 ($MILLION)
FIGURE 29. INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, 2018-2026 ($MILLION)
FIGURE 30. REST OF ASIA-PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, 2018-2026 ($MILLION)
FIGURE 31. BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, 2018-2026 ($MILLION)
FIGURE 32. SOUTH AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, 2018-2026 ($MILLION)
FIGURE 33. SAUDI ARABIA PHARMACEUTICAL DRUG DELIVERY MARKET, 2018-2026 ($MILLION)
FIGURE 34. REST OF LAMEA PHARMACEUTICAL DRUG DELIVERY MARKET, 2018-2026 ($MILLION)
FIGURE 35. BAYER: NET SALES, 2016–2018 ($MILLION)
FIGURE 36. BAYER: REVENUE SHARE BY SEGMENTS, 2018(%)
FIGURE 37. BAYER: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 38. BD: NET SALES, 2016–2018 ($MILLION)
FIGURE 39. BD: REVENUE SHARE BY SEGMENTS, 2018 (%)
FIGURE 40. BD: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 41. ROCHE: NET SALES, 2016–2018 ($MILLION)
FIGURE 42. ROCHE: REVENUE SHARE BY SEGMENT, 2018(%)
FIGURE 43. ROCHE: REVENUE SHARE BY REGION, 2018(%)
FIGURE 44. GSK: NET SALES, 2017–2018 ($MILLION)
FIGURE 45. GSK REVENUE SHARE BY SEGMENTS, 2018 (%)
FIGURE 46. GSK: REVENUE SHARE BY REGIONS, 2018 (%)
FIGURE 47. J&J: NET SALES, 2016–2018 ($MILLION)
FIGURE 48. J&J: REVENUE SHARE BY SEGMENTS, 2018 (%)
FIGURE 49. J&J: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 50. MERCK: NET SALES, 2016–2018 ($MILLION)
FIGURE 51. MERCK: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 52. MERCK: REVENUE SHARE BY REGION, 2018(%)
FIGURE 53. NOVARTIS AG: NET SALES, 2016–2018 ($MILLION)
FIGURE 54. NOVARTIS AG: REVENUE SHARE BY REGION, 2018(%)
FIGURE 55. NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 56. 3M: NET SALES, 2016–2018 ($MILLION)
FIGURE 57. 3M: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 58. 3M: REVENUE SHARE BY REGION, 2018(%)
FIGURE 59. PFIZER: NET SALES, 2016–2018 ($MILLION)
FIGURE 60. PFIZER: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 61. PFIZER: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 62. SANOFI: NET SALES, 2016–2018 ($MILLION)
FIGURE 63. SANOFI: REVENUE SHARE BY SEGMENTS, 2018 (%)
FIGURE 64. SANOFI: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 01. GLOBAL PHARMACEUTICAL DRUG DELIVERY MARKET SEGMENTATION
FIGURE 02. TOP PLAYER POSITIONING, 2018
FIGURE 03. TOP INVESTMENT POCKETS
FIGURE 04. MODERATE BARGAINING POWER OF SUPPLIER
FIGURE 05. LOW BARGAINING POWER OF BUYERS
FIGURE 06. LOW THREAT OF SUBSTITUTES
FIGURE 07. HIGH INTENSITY OF RIVALRY
FIGURE 08. LOW THREAT OF NEW ENTRANT
FIGURE 09. IMPACT ANALYSES, PHARMACEUTICAL DRUG DELIVERY MARKET
FIGURE 10. COMPARATIVE SHARE ANALYSIS OF ORAL PHARMACEUTICAL DRUG DELIVERY MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 11. COMPARATIVE SHARE ANALYSIS OF NASAL PHARMACEUTICAL DRUG DELIVERY MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF OCULAR PHARMACEUTICAL DRUG DELIVERY MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF TOPICAL PHARMACEUTICAL DRUG DELIVERY MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF OTHERS PHARMACEUTICAL DRUG DELIVERY MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 15. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL DRUG DELIVERY MARKET FOR CANCER, BY COUNTRY, 2018 & 2026 (%)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL DRUG DELIVERY MARKET FOR DIABETES, BY COUNTRY, 2018 & 2026 (%)
FIGURE 17. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL DRUG DELIVERY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2018 & 2026 (%)
FIGURE 18. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL DRUG DELIVERY MARKET FOR OTHERS, BY COUNTRY, 2018 & 2026 (%)
FIGURE 19. U.S. PHARMACEUTICAL DRUG DELIVERY MARKET, 2018-2026 ($MILLION)
FIGURE 20. CANADA PHARMACEUTICAL DRUG DELIVERY MARKET, 2018-2026 ($MILLION)
FIGURE 21. MEXICO PHARMACEUTICAL DRUG DELIVERY MARKET, 2018-2026 ($MILLION)
FIGURE 22. GERMANY PHARMACEUTICAL DRUG DELIVERY MARKET, 2018-2026 ($MILLION)
FIGURE 23. FRANCE PHARMACEUTICAL DRUG DELIVERY MARKET, 2018-2026 ($MILLION)
FIGURE 24. UK PHARMACEUTICAL DRUG DELIVERY MARKET, 2018-2026 ($MILLION)
FIGURE 25. ITALY PHARMACEUTICAL DRUG DELIVERY MARKET, 2018-2026 ($MILLION)
FIGURE 26. REST OF EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, 2018-2026 ($MILLION)
FIGURE 27. JAPAN PHARMACEUTICAL DRUG DELIVERY MARKET, 2018-2026 ($MILLION)
FIGURE 28. CHINA PHARMACEUTICAL DRUG DELIVERY MARKET, 2018-2026 ($MILLION)
FIGURE 29. INDIA PHARMACEUTICAL DRUG DELIVERY MARKET, 2018-2026 ($MILLION)
FIGURE 30. REST OF ASIA-PACIFIC PHARMACEUTICAL DRUG DELIVERY MARKET, 2018-2026 ($MILLION)
FIGURE 31. BRAZIL PHARMACEUTICAL DRUG DELIVERY MARKET, 2018-2026 ($MILLION)
FIGURE 32. SOUTH AFRICA PHARMACEUTICAL DRUG DELIVERY MARKET, 2018-2026 ($MILLION)
FIGURE 33. SAUDI ARABIA PHARMACEUTICAL DRUG DELIVERY MARKET, 2018-2026 ($MILLION)
FIGURE 34. REST OF LAMEA PHARMACEUTICAL DRUG DELIVERY MARKET, 2018-2026 ($MILLION)
FIGURE 35. BAYER: NET SALES, 2016–2018 ($MILLION)
FIGURE 36. BAYER: REVENUE SHARE BY SEGMENTS, 2018(%)
FIGURE 37. BAYER: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 38. BD: NET SALES, 2016–2018 ($MILLION)
FIGURE 39. BD: REVENUE SHARE BY SEGMENTS, 2018 (%)
FIGURE 40. BD: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 41. ROCHE: NET SALES, 2016–2018 ($MILLION)
FIGURE 42. ROCHE: REVENUE SHARE BY SEGMENT, 2018(%)
FIGURE 43. ROCHE: REVENUE SHARE BY REGION, 2018(%)
FIGURE 44. GSK: NET SALES, 2017–2018 ($MILLION)
FIGURE 45. GSK REVENUE SHARE BY SEGMENTS, 2018 (%)
FIGURE 46. GSK: REVENUE SHARE BY REGIONS, 2018 (%)
FIGURE 47. J&J: NET SALES, 2016–2018 ($MILLION)
FIGURE 48. J&J: REVENUE SHARE BY SEGMENTS, 2018 (%)
FIGURE 49. J&J: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 50. MERCK: NET SALES, 2016–2018 ($MILLION)
FIGURE 51. MERCK: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 52. MERCK: REVENUE SHARE BY REGION, 2018(%)
FIGURE 53. NOVARTIS AG: NET SALES, 2016–2018 ($MILLION)
FIGURE 54. NOVARTIS AG: REVENUE SHARE BY REGION, 2018(%)
FIGURE 55. NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 56. 3M: NET SALES, 2016–2018 ($MILLION)
FIGURE 57. 3M: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 58. 3M: REVENUE SHARE BY REGION, 2018(%)
FIGURE 59. PFIZER: NET SALES, 2016–2018 ($MILLION)
FIGURE 60. PFIZER: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 61. PFIZER: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 62. SANOFI: NET SALES, 2016–2018 ($MILLION)
FIGURE 63. SANOFI: REVENUE SHARE BY SEGMENTS, 2018 (%)
FIGURE 64. SANOFI: REVENUE SHARE BY REGION, 2018 (%)
